Diabetic Nephropathy

Sitagliptin Better for Glycemic Control in T2D With Renal Impairment

Sitagliptin Better for Glycemic Control in T2D With Renal Impairment

Study results indicated that sitagliptin showed greater glycemic efficacy than dapagliflozin treatment.

ADA, EASD Issue New Recommendations for T2DM

ADA, EASD Issue New Recommendations for T2DM

Additional focus on lifestyle management, self-management education and support emphasized

High Phosphorus Predicts Diabetic Nephropathy Progression

High Phosphorus Predicts Diabetic Nephropathy Progression

By

Highest vs lowest quartile of serum phosphorus is independently associated with a nearly 3-fold increased risk of diabetic nephropathy progression.

Cardiovascular Event Rates Vary by Kidney Failure Cause

Cardiovascular Event Rates Vary by Kidney Failure Cause

By

Among US dialysis patients, cardiovascular event rates are highest in those with diabetic nephropathy and lowest among those with IgA nephropathy.

Canagliflozin Trial for T2D, CKD Halted Due to Positive Results

Canagliflozin Trial for T2D, CKD Halted Due to Positive Results

A clinical trial assessing canagliflozin (Invokana; Janssen) as an addition to standard-of-care in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) has been stopped early after meeting its pre-specified efficacy criteria.

Trulicity Labeling Updated to Include Data on T2D Patients With CKD

Trulicity Labeling Updated to Include Data on T2D Patients With CKD

In the AWARD-7 trial, patients who received Trulicity 0.75mg or 1.5mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss vs patients who received traditional basal-bolus insulin.

Dulaglutide Assessed for Type 2 Diabetes With CKD

Dulaglutide Assessed for Type 2 Diabetes With CKD

Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist.

Diabetic ESRD Linked to Elevated Fibrinogen

Diabetic ESRD Linked to Elevated Fibrinogen

By

Patients with higher levels of serum fibrinogen have higher rates of progression.

More Rapid Decline in Kidney Function for Diagnosed Diabetes

More Rapid Decline in Kidney Function for Diagnosed Diabetes

Much steeper decline in adjusted mean eGFR for those with diagnosed diabetes versus those without.

Metformin Can Be Used Safely at Lower Levels of Renal Function

Metformin Can Be Used Safely at Lower Levels of Renal Function

By

New study shows metformin is not associated with an increased risk of acidosis in patients with type 2 diabetes and an eGFR of 30 to 60 mL/min/1.73 m2.

Gestational Diabetes May Indicate Future Subclinical Renal Issues

Gestational Diabetes May Indicate Future Subclinical Renal Issues

Women who had gestational diabetes more likely to show increased eGFR levels many years postpartum

Novel Signal ID'd for Microalbuminuria in Europeans With T2DM

Novel Signal ID'd for Microalbuminuria in Europeans With T2DM

Genome-wide association study identified novel signal near GABRR1, which was not seen in Asians.

Study: ESRD Risk in Type 1 Diabetes Pts Has Declined

Study: ESRD Risk in Type 1 Diabetes Pts Has Declined

Relative risk of end-stage renal disease was 0.13 in those diagnosed in 1995-2011 versus 1965-1979.

SHPT Highly Prevalent Among Diabetic Nephropathy Patients

SHPT Highly Prevalent Among Diabetic Nephropathy Patients

By

Nearly 86% of diabetic nephropathy patients from an Egyptian outpatient center had elevated iPTH levels.

End-Stage Renal Disease From Diabetes Declined in US

End-Stage Renal Disease From Diabetes Declined in US

2000 to 2014 saw decrease in incidence of ESRD with diabetes listed as the primary cause.

Anemia Risk Factors in Diabetic Nephropathy Patients Identified

Anemia Risk Factors in Diabetic Nephropathy Patients Identified

By

Proteinuria and renin-angiotensin-aldosterone system inhibitors are independently associated with a significant 6-fold increased odds for anemia in patients with diabetic nephropathy.

Glycemic Control Intensity Does Not Influence ESRD, Mortality

Glycemic Control Intensity Does Not Influence ESRD, Mortality

By

End-stage renal disease developed in similar proportions of diabetics regardless of whether they had intensive or standard glycemic control.

Biomarkers Predict Rapid Renal Decline in Type 2 Diabetes

Biomarkers Predict Rapid Renal Decline in Type 2 Diabetes

Biomarkers apoA4, CD5L, C1QB, and IBP3 may improve the prediction of rapid decline in renal function independently of recognized clinical risk factors in T2DM.

Liraglutide Linked With Lower Diabetic Kidney Disease Risk

Liraglutide Linked With Lower Diabetic Kidney Disease Risk

By

Liraglutide-treated patients were 22% less likely than placebo recipients to experience a composite outcome of renal events.

Adynamic Bone Disease Prevalent in Type 2 Diabetes Patients With CKD

Adynamic Bone Disease Prevalent in Type 2 Diabetes Patients With CKD

By

Almost 40% of pre-dialysis patients with stage 4-5 CKD patients and type 2 diabetes had lab results suggesting low turnover bone disease.

Low Tryptophan May Signal Diabetic Nephropathy

Low Tryptophan May Signal Diabetic Nephropathy

There was a significant association for Trp with the event of rapid decline in eGFR.

sRAGE May Increase Risk of Diabetic Nephropathy

sRAGE May Increase Risk of Diabetic Nephropathy

Higher levels of sRAGE were significantly associated with incidence of DN after adjustment for duration of diabetes.

Children With Diabetic Ketoacidosis at High Risk of AKI

Children With Diabetic Ketoacidosis at High Risk of AKI

Of the children who developed acute kidney injury, 34.9% had stage 1, 45.3% had stage 2, and 19.8% had stage 3.

Increased Use of DPP-4, SGLT-2 Inhibitors for Diabetic Nephropathy

Increased Use of DPP-4, SGLT-2 Inhibitors for Diabetic Nephropathy

DPP-4 inhibitors use was used in 54% of treatment visits by the last quarter of 2014; ACEIs and ARBs were prescribed in the majority of treatment visits with peaks above 90%.

Valsartan Reduces Microalbuminuria in IGT Patients

Valsartan Reduces Microalbuminuria in IGT Patients

Valsartan reduced the incidence of microalbuminuria in IGT without increasing the incidence of hyperkalemia or renal dysfunction compared with placebo.

T2DM Microvascular Complications Linked to Periodontitis Severity

T2DM Microvascular Complications Linked to Periodontitis Severity

Poor glycemic control linked to increased prevalence and severity of periodontitis.

Liraglutide Found to Reduce Albuminuria in Diabetes Patients

Liraglutide Found to Reduce Albuminuria in Diabetes Patients

By

Use of the glucagon-like peptide-1 receptor agonist lowered 24-hour urinary albumin excretion rate by 32% over 12 weeks versus placebo.

Low HDL-C, High Triglycerides Up Risk for Diabetic Kidney Disease

Low HDL-C, High Triglycerides Up Risk for Diabetic Kidney Disease

Findings in large cohort of patients with diabetes over 4 years of follow-up.

Advanced Glycation End-Products Predict Renal Function Decline

Advanced Glycation End-Products Predict Renal Function Decline

AGEs improve RFL prediction in American-Indians with type 2 diabetes.

Diabetic Kidney Disease Rates in US Hold Steady

Diabetic Kidney Disease Rates in US Hold Steady

No change in overall prevalence from 1988 to 2014; decrease in albuminuria, increase in reduced eGFR.

Sign Up for Free e-newsletters